Avadel Pharmaceuticals plc [NASDAQ: AVDL] plunged by -$1.53 during the normal trading session on Thursday and reaching a high of $23.0 during the day while it closed the day at $21.4.
Avadel Pharmaceuticals plc stock has also loss -7.36% of its value over the past 7 days. However, AVDL stock has inclined by 46.37% in the 3 months of the year. Over the past six months meanwhile, it has gained 132.10% and gained 83.53% year-on date.
The market cap for AVDL stock reached $2.09 billion, with 97.23 million shares outstanding and 93.28 million shares in the current float. Compared to the average trading volume of 2.72M shares, AVDL reached a trading volume of 8913382 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Avadel Pharmaceuticals plc [AVDL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AVDL shares is $21.06 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AVDL stock is a recommendation set at 3.09. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Avadel Pharmaceuticals plc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 23, 2025. While these analysts kept the previous recommendation, Wells Fargo raised their target price to Equal Weight. The new note on the price target was released on September 03, 2025, representing the official price target for Avadel Pharmaceuticals plc stock. Previously, the target price had yet another raise to $22, while H.C. Wainwright analysts kept a Buy rating on AVDL stock.
The Price to Book ratio for the last quarter was 21.18, with the Price to Cash per share for the same quarter was set at 0.94. Price to Free Cash Flow for AVDL in the course of the last twelve months was 56.81 with Quick ratio for the last quarter at 2.37.
AVDL stock trade performance evaluation
Avadel Pharmaceuticals plc [AVDL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.36. With this latest performance, AVDL shares gained by 15.12% in over the last four-week period, additionally plugging by 132.10% over the last 6 months – not to mention a rise of 103.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AVDL stock in for the last two-week period is set at 60.41, with the RSI for the last a single of trading hit 0.65, and the three-weeks RSI is set at 0.58 for Avadel Pharmaceuticals plc [AVDL]. The present Moving Average for the last 50 days of trading for this stock 17.81, while it was recorded at 22.64 for the last single week of trading, and 11.99 for the last 200 days.
Avadel Pharmaceuticals plc [AVDL]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Avadel Pharmaceuticals plc [AVDL] shares currently have an operating margin of 1.82% and a Gross Margin at 94.47%. Avadel Pharmaceuticals plc’s Net Margin is presently recorded at -0.11%.
Avadel Pharmaceuticals plc (AVDL) Capital Structure & Debt Analysis
According to recent financial data for Avadel Pharmaceuticals plc. ( AVDL), the Return on Equity (ROE) stands at -0.32%, reflecting a slight decline for investors. The Return on Assets (ROA) is -0.16%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Avadel Pharmaceuticals plc’s Return on Invested Capital (ROIC) is -0.21%, showcasing its effectiveness in deploying capital for earnings.
Avadel Pharmaceuticals plc (AVDL) Efficiency & Liquidity Metrics
Based on Avadel Pharmaceuticals plc’s (AVDL) latest financial statements, the Debt-to-Equity Ratio is 0.38%, indicating its reliance on debt financing relative to shareholder equity.
Avadel Pharmaceuticals plc (AVDL) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Avadel Pharmaceuticals plc. (AVDL) effectively leverages its workforce, generating an average of -$1489.36 per employee. The company’s liquidity position is robust, with a Current Ratio of 2.76% and a Quick Ratio of 2.37%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Avadel Pharmaceuticals plc [AVDL] stock
With the latest financial reports released by the company, Avadel Pharmaceuticals plc posted -0.05/share EPS, while the average EPS was predicted by analysts to be reported at -0.04/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AVDL.
Avadel Pharmaceuticals plc [AVDL]: Institutional Ownership
There are presently around $90.08%, or 94.60%% of AVDL stock, in the hands of institutional investors. The top three institutional holders of AVDL stocks are: JANUS HENDERSON GROUP PLC with ownership of 13.3 million shares, which is approximately 13.8296%. POLAR CAPITAL HOLDINGS PLC, holding 6.56 million shares of the stock with an approximate value of $$92.24 million in AVDL stocks shares; and POLAR CAPITAL HOLDINGS PLC, currently with $$80.71 million in AVDL stock with ownership which is approximately 5.9699%.
